Ascelia Pharma announced today that the FDA has scheduled a Type A meeting for 9 September 2026 to discuss the Complete Response Letter issued in early July regarding the Orviglance NDA. The company has submitted a briefing package addressing each of the topics raised by the agency, covering statistical and clinical, product quality and regulatory considerations. Ascelia intends to update the market once it receives the official meeting minutes, which the FDA normally issues around 30 days after the meeting.

Two things change with today's announcement. The first is timing. Since the CRL, the case has had no fixed calendar. There is now a date, and a realistic point at which investors receive substantive information, which is early October when the minutes arrive rather than the meeting itself. The second is that the company has set out the position it intends to argue.

Ascelia is not signalling that it rules out a further re-read or a new study. It states that the NDA is supported by substantial evidence and that the totality of the clinical, safety and imaging data supports approval, which is close to standard language after a CRL and does not by itself close off any particular remedy. The briefing package addresses the three clinical objections in the CRL on their own terms, namely the scientific justification for the re-read, the training of the new readers, and the demonstration of clinical utility. It also sets out the rationale for using T1-weighted imaging as the basis for assessing improvement in focal liver lesion visualisation for a T1-enhancing agent.

Measured against the four scenarios we set out in July, this is the company arguing at the faster end of the range, where the FDA's concerns are resolved without new analysis of the imaging data.

Read our July update here: https://www.inderes.dk/analyst-comments/ascelia-pharma-market-is-pricing-the-downside-but-the-crl-letter-and-management-commentary-still-support-better-scenarios

The company has prepared a detailed briefing package addressing each topic in the CRL and has implemented the product quality actions requested, so even on the most favourable outcome of the meeting the NDA would be updated and resubmitted rather than approved as originally filed. On that basis the best outcome is a resubmission with minor changes, and the middle path, a prospectively designed and properly controlled re-read of the existing full-sequence images, appears to be the fallback rather than the opening position.

One element has genuinely improved. On product quality, Ascelia states that it has aligned with the FDA's recommendations and implemented the actions requested. Product documentation was one of the two areas of deficiency named when the CRL was first disclosed, and if the agency agrees that it is closed, the clinical and statistical question stands alone as the open issue.

On the clinical argument itself, the T1 rationale that the company now puts forward publicly is consistent with the reading we set out in July, that the deficiency the FDA identifies is methodological rather than substantive. Manganese expresses its contrast effect on T1 imaging by mechanism, and the full sequence set including T2 and diffusion-weighted imaging was acquired in line with the study protocol. The balancing point remains that the FDA's underlying question is whether post-contrast imaging adds clinical utility beyond the non-T1 standard of care, and that comparison is one the agency asked to see performed. Presenting the case for why T1 is the appropriate basis of comparison is a legitimate scientific position, but it leaves more to be settled at the meeting than running the comparison would. That tension is precisely what the 9 September meeting has to resolve.

Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a Digital IR/Corporate Visibility subscription agreement. Michael Friis, 17/08-2026, kl. 19:01